The La protein counteracts cisplatin-induced cell death by stimulating protein synthesis of anti-apoptotic factor Bcl2

Oncotarget

Volumn 7, Issue 20, 2016, Pages 29664-29676

  Heise, Tilman ^a   Kota, Venkatesh ^a   Brock, Alexander ^a   Morris, Amanda B ^a   Rodriguez, Reycel M ^a   Zierk, Avery W ^a   Howe, Philip H ^a   Sommer, Gunhild ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cisplatin; La SSB; LARP3; mRNA translation; RNA binding protein

Indexed keywords

CISPLATIN; LA ANTIGEN; MESSENGER RNA; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; AUTOANTIGEN; BCL2 PROTEIN, HUMAN; LA PROTEIN, HUMAN (349-364); PEPTIDE FRAGMENT;

5' UNTRANSLATED REGION; ARTICLE; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; DRUG SENSITIVITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RNA SEQUENCE; RNA STRUCTURE; RNA TRANSLATION; SQUAMOUS CELL CARCINOMA CELL LINE; TRANSIENT EXPRESSION; TRANSLATION START SITE; BIOSYNTHESIS; DRUG RESISTANCE; HEAD AND NECK TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; AUTOANTIGENS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; PEPTIDE FRAGMENTS; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-BCL-2; UP-REGULATION;

EID: 84969895693     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8819     Document Type: Article

References (50)

1. Trotta R, Vignudelli T, Candini O, Intine RV, Pecorari L, Guerzoni C, Santilli G, Byrom MW, Goldoni S, Ford LP et al. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell. 2003; 3: 145-160.
2. Sommer G, Dittmann J, Kuehnert J, Reumann K, Schwartz PE, Will H, Coulter BL, Smith MT and Heise T. The RNAbinding protein La contributes to cell proliferation and CCND1 expression. Oncogene. 2011; 30: 434-444.
3. Sommer G, Rossa C, Chi AC, Neville BW and Heise T. Implication of RNA-binding protein La in proliferation, migration and invasion of lymph node-metastasized hypopharyngeal SCC cells. PloS One. 2011; 6: e25402.
4. Petz M, Them N, Huber H, Beug H and Mikulits W. La enhances IRES-mediated translation of laminin B1 during malignant epithelial to mesenchymal transition. Nucleic Acids Res. 2012; 40: 290-302.
5. Petz M, Them NC, Huber H and Mikulits W. PDGF enhances IRES-mediated translation of Laminin B1 by cytoplasmic accumulation of La during epithelial to mesenchymal transition. Nucleic Acids Res. 2012; 40: 9738-9749.
6. Wolin SL and Cedervall T. The La protein. Annu Rev Biochem. 2002; 71: 375-403.
7. Bayfield MA, Yang R and Maraia RJ. Conserved and divergent features of the structure and function of La and La-related proteins (LARPs). Biochim Biophys Acta. 2010; 1799: 365-378.
8. Bayfield MA, Kaiser TE, Intine RV and Maraia RJ. Conservation of a masked nuclear export activity of La proteins and its effects on tRNA maturation. Mol Cell Biol. 2007; 27: 3303-3312.
9. Liang C, Xiong K, Szulwach KE, Zhang Y, Wang Z, Peng J, Fu M, Jin P, Suzuki HI and Liu Q. Sjogren syndrome antigen B (SSB)/La promotes global microRNA expression by binding microRNA precursors through stem-loop recognition. J Biol Chem. 2013; 288: 723-736.
10. Ali N and Siddiqui A. The La antigen binds 5-noncoding region of the hepatitis C virus RNA in the context of the initiator AUG codon and stimulates internal ribosome entry site-mediated translation. Proc Natl Acad Sci U S A. 1997; 94: 2249-2254.
11. Costa-Mattioli M, Svitkin Y and Sonenberg N. La autoantigen is necessary for optimal function of the poliovirus and hepatitis C virus internal ribosome entry site in vivo and in vitro. Mol Cell Biol. 2004; 24: 6861-6870.
12. Holcik, M and Korneluk, RG. Functional characterization of the X-linked inhibitor of apoptosis (XIAP) internal ribosome entry site element: role of La autoantigen in XIAP translation. Mol Cell Biol. 2000; 20: 4648-4657.
13. Belsham, GJ, Sonenberg N and Svitkin YV. The role of the La autoantigen in internal initiation. Curr Top Microbiol. 1995; 203: 85-98.
14. Meerovitch K, Svitkin YV, Lee HS, Lejbkowicz F, Kenan DJ, Chan EK, Agol VI, Keene JD and Sonenberg N. La autoantigen enhances and corrects aberrant translation of poliovirus RNA in reticulocyte lysate. J Virol. 1993; 67: 3798-3807.
15. Svitkin YV, Meerovitch K, Lee HS, Dholakia JN, Kenan DJ, Agol VI and Sonenberg N. Internal translation initiation on poliovirus RNA: further characterization of La function in poliovirus translation in vitro. J Virol. 1994; 68: 1544-1550.
16. Svitkin YV, Pause A and Sonenberg N. La autoantigen alleviates translational repression by the 5-leader sequence of the human immunodeficiency virus type 1 mRNA. J Virol. 1994; 68: 7001-7007.
17. Ali N, Pruijn GJ, Kenan DJ, Keene JD and Siddiqui A. Human La antigen is required for the hepatitis C virus internal ribosome entry site-mediated translation. J Biol Chem. 2000; 275: 27531-27540.
18. Kim YK, Back SH, Rho J, Lee SH and Jang SK. La autoantigen enhances translation of BiP mRNA. Nucleic Acids Res. 2001; 29: 5009-5016.
19. Pudi R, Srinivasan P and Das S. La protein binding at the GCAC site near the initiator AUG facilitates the ribosomal assembly on the hepatitis C virus RNA to influence internal ribosome entry site-mediated translation. J Biol Chem. 2004; 279: 29879-29888.
20. Martino L, Pennell S, Kelly G, Bui TT, Kotik-Kogan O, Smerdon SJ, Drake AF, Curry S and Conte MR. Analysis of the interaction with the hepatitis C virus mRNA reveals an alternative mode of RNA recognition by the human La protein. Nucleic Acids Res. 2012; 40: 1381-1394.
21. Kuehnert J, Sommer G, Zierk AW, Fedarovich A, Brock A, Fedarovich D and Heise T. Novel RNA chaperone domain of RNA-binding protein La is regulated by AKT phosphorylation. Nucleic Acids Res. 2015; 43: 581-594.
22. Huhn P, Pruijn GJ, van Venrooij WJ and Bachmann M. Characterization of the autoantigen La (SS-B) as a dsRNA unwinding enzyme. Nucleic Acids Res. 1997; 25: 410-416.
23. Bachmann M, Pfeifer K, Schroder HC and Muller WE. Characterization of the autoantigen La as a nucleic aciddependent ATPase/dATPase with melting properties. Cell. 1990; 60: 85-93.
24. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31: 1869-1883.
25. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22: 7265-7279.
26. Owens TW, Gilmore AP, Streuli CH and Foster FM. Inhibitor of Apoptosis Proteins: Promising Targets for Cancer Therapy. J Carcinog Mutagen. 2013.
27. Wood J, Lee SS and Hague A. Bag-1 proteins in oral squamous cell carcinoma. Oral Oncol. 2009; 45: 94-102.
28. Plati J, Bucur O and Khosravi-Far R. Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem. 2008; 104: 1124-1149.
29. Townsend PA, Stephanou A, Packham G and Latchman DS. BAG-1: a multi-functional pro-survival molecule. Int J Biochem Cell Biol. 2005; 37: 251-259.
30. Igney FH and Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nature rev. Cancer. 2002; 2: 277-288.
31. Ashimori N, Zeitlin BD, Zhang Z, Warner K, Turkienicz IM, Spalding AC, Teknos TN, Wang S and Nor JE. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol Cancer Ther. 2009; 8: 893-903.
32. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer discov. 2014; 4: 362-375.
33. Craig AW, Svitkin YV, Lee HS, Belsham GJ and Sonenberg N. The La autoantigen contains a dimerization domain that is essential for enhancing translation. Mol Cell Biol. 1997; 17: 163-169.
34. Sherrill KW, Byrd MP, Van Eden ME and Lloyd RE. BCL-2 translation is mediated via internal ribosome entry during cell stress. J Biol Chem. 2004; 279: 29066-29074.
35. Wang NS, Unkila MT, Reineks EZ and Distelhorst CW. Transient expression of wild-type or mitochondrially targeted Bcl-2 induces apoptosis, whereas transient expression of endoplasmic reticulum-targeted Bcl-2 is protective against Bax-induced cell death. J Biol Chem. 2001; 276: 44117-44128.
36. Uhlmann EJ, Subramanian T, Vater CA, Lutz R and Chinnadurai G. A potent cell death activity associated with transient high level expression of BCL-2. J Biol Chem. 1998; 273: 17926-17932.
37. Shinoura N, Yoshida Y, Nishimura M, Muramatsu Y, Asai A, Kirino T and Hamada H. Expression level of Bcl-2 determines anti-or proapoptotic function. Cancer Res. 1999; 59: 4119-4128.
38. Pudi R, Abhiman S, Srinivasan N and Das S. Hepatitis C virus internal ribosome entry site-mediated translation is stimulated by specific interaction of independent regions of human La autoantigen. J Biol Chem. 2003; 278: 12231-12240.
39. McBratney S and Sarnow P. Evidence for involvement of trans-acting factors in selection of the AUG start codon during eukaryotic translational initiation. Mol Cell Biol. 1996; 16: 3523-3534.
40. Rebucci M and Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol. 2013; 85: 1219-1226.
41. Hopkins TG, Mura M, Al-Ashtal HA, Lahr RM, Abd-Latip N, Sweeney K, Lu H, Weir J, El-Bahrawy M, Steel JH et al. The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer. Nucleic Acids Res. 2016; 44: 1227-1246.
42. Cimmino A, Calin GA, Fabbri M, Iorio M., Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102: 13944-13949.
43. Villar J, Quadri HS, Song I, Tomita Y, Tirado OM and Notario V. PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization. Cancer Res. 2009; 69: 102-110.
44. Carey TE, Kimmel KA, Schwartz DR, Richter DE, Baker SR and Krause CJ. Antibodies to human squamous cell carcinoma. Otolaryngol Head Neck Surg. 1983; 91: 482-491.
45. Horke S, Reumann K, Schweizer M, Will H and Heise T. Nuclear trafficking of La protein depends on a newly identified nucleolar localization signal and the ability to bind RNA. J Biol Chem. 2004; 279: 26563-26570.
46. Yoon JH, Abdelmohsen K, Srikantan S, Yang X, Martindale JL, De S, Huarte M, Zhan M, Becker KG and Gorospe M. LincRNA-p21 suppresses target mRNA translation. Mol Cell. 2012; 47: 648-655.
47. Bachmann M, Troster H, Bartsch H and Grolz D. A frame shift mutation in a hot spot region of the nuclear autoantigen La (SS-B). J Autoimmun. 1996; 9: 747-756.
48. Weser S, Bachmann M, Seifart KH and Meissner W. Transcription efficiency of human polymerase III genes in vitro does not depend on the RNP-forming autoantigen La. Nucleic Acids Res. 2000; 28: 3935-3942.
49. Schott J, Reitter S, Philipp J, Haneke K, Schafer H and Stoecklin G. Translational regulation of specific mRNAs controls feedback inhibition and survival during macrophage activation. PLoS Genetics. 2014; 10: e1004368.
50. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003; 31: 3406-3415.